AI Science Tracker
EN

Development and validation of machine learning models for predicting STAS in stage I lung adenocarcinoma with part-solid and solid nodules: a two-center study.

Affiliation not stated in the reviewed material · 29 Oct 2025 · medicine

Discovery

Development and validation of machine learning models for predicting STAS in stage I lung adenocarcinoma with part-solid and solid nodules: a two-center study.

Source check: Source checked. Not independent scientific confirmation.

Finding: Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction. The bibliographic records retrieved do not state an author affiliation.

Technology: Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.
Test and result
Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction.
Limitation / still unknown
Original Frontiers Methods/Results: ML models predict STAS in stage-I lung adenocarcinoma using 353-patient training data and independent 120-patient second-center validation; tuning used stratified 10-fold CV in training only. Retrospective multicenter validation; narrow diagnostic prediction. Methods/Results specify cohort, reference/outcome, split or experimental comparator and limitations.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1682633/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.